WO1999012468A1 - Method and apparatus for measuring myocardial impairment and dysfunctions from efficiency and performance diagrams - Google Patents
Method and apparatus for measuring myocardial impairment and dysfunctions from efficiency and performance diagrams Download PDFInfo
- Publication number
- WO1999012468A1 WO1999012468A1 PCT/US1997/015807 US9715807W WO9912468A1 WO 1999012468 A1 WO1999012468 A1 WO 1999012468A1 US 9715807 W US9715807 W US 9715807W WO 9912468 A1 WO9912468 A1 WO 9912468A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cardiac
- efficiency
- curve
- subject
- data point
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H40/00—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices
- G16H40/60—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices
- G16H40/63—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for local operation
Definitions
- the present invention relates to a cardiac monitor and, more specifically, to a method and apparatus for diagnosis of the degree of myocardial impairment, dysfunction, and the state of critical illness of a subject from efficiency and performance diagrams.
- U.S. Patent 5,370,122 Disclosed in U.S. Patent 5,370,122 is a method and an apparatus to establish the synergy of measured parameters in the form of cardiac pressure- size curves. Deviations of instant pressure-size curves from basal pressure-size curves produce changes in the numerical values of cardiac efficiency, indicative of myocardial impairment, and in the numerical values of cardiac work, indicative of dysfunctions. Not disclosed in the '122 patent, however, is the synergy of cardiac efficiency, myocardial oxygen consumption and cardiac power into a single reference frame allowing for diagnosis of dysfunctions, myocardial impairments and critical illness.
- a cardiac diagnostic device for diagnosis of myocardial impairment, dysfunctions, and critical illness.
- the device provides means for producing and measuring signals representative of ventricular size, pressures, time intervals of heart beat, and heart rate from a subject, means for processing said signals, means to determine efficiency and performance diagrams from the processed signals, means for determining pressure, volume, and cardiac efficiencies from the efficiency diagram for diagnosing myocardial impairment, means for determining cardiac work, ventricular energy, and myocardial oxygen consumption for diagnosing dysfunctions and critical illness from the performance diagram, means for standardizing ventricular work and ventricular energy and ventricular myocardial oxygen consumption with respect to preselected reference values, and means such as audible or visual signals to alert upon the attainment of specific levels of myocardial impairment and dysfunctions or critical illness.
- FIG. 1 illustrates an efficiency diagram used to determine cardiac efficiencies and its components volume efficiency and pressure efficiency for diagnosing myocardial impairment
- FIG. 2 illustrates a performance diagram used to determine ventricular energy, its metabolic equivalent of myocardial oxygen consumption, and cardiac work for diagnosing dysfunctions and the state of critical illness;
- FIG. 3 shows a block diagram of the apparatus to practice the instant invention
- FIG. 4 illustrates the utility of the present invention to diagnose cardiac efficiency of an exercising subject, to design rehabilitation and exercising programs, and to determine the intensity levels for beneficial exercise;
- FIG. 5 illustrates the utility of the present invention to diagnose myocardial impairment and dysfunction, design and monitoring of therapies, and drug interventions.
- EDVI is the end-diastolic volume index
- ESVI is the end-systolic volume index
- SBP is the systolic blood pressure
- EDP is the end-diastolic pressure.
- EDVI and ESVI may be expressed as the ratio of end- diastolic volume, EDV/BSA and end-systolic volume ESV/BSA where BSA is the body surface area.
- CF EF(V) * EF(P) (3)
- Cardiac work expended during the time of one heart beat is given by the ratio of W and the time required for one beat (RR) .
- cardiac work per minute (CP) is given by the product of W and heart rate (HR) .
- CP W*HR (4)
- volume efficiency is plotted versus pressure efficiency. Curves are added to interconnect points in the efficiency diagram having equal values of the product EF(V) and EF(P) or equal values of CF, according to equation (3) . Further, basal values of volume and pressure efficiency are added to the efficiency diagram as horizontal and vertical lines.
- the efficiency diagram curves can be produced either as a function of the computer program or as a transparent overlay on the monitor.
- CF is plotted versus EDVI*SBP*HR or, alternatively, versus MV0 2 .
- Curves are added to interconnect points in the performance diagram having equal values of CP.
- basal values for CF and MV0 2 are added as horizontal and vertical lines.
- the curves of the performance diagram can be produced either as a function of the computer program or as a transparent overlay on the monitor.
- sensors 2 are placed on a subject 1 to detect signals representative of end-diastolic volume, end-systolic volume, systolic blood pressure, end- diastolic blood pressure, time for one heart cycle, and heart rate which are transmitted on multi-line wire 3 to computer 4.
- sensors 2 may include catheters, ultra-sound equipment, and pressure transducers as required for differential assessment of the left or right heart. Additional input representative of patient information including weight, height, body surface area, and preselected basal values is provided from a keyboard 5 to computer 4 on line 6.
- Computer 4 is programmed to process all incoming signals for determination of volume efficiency, pressure efficiency, cardiac efficiency, cardiac work, ventricular energy, and ventricular myocardial oxygen consumption, said parameters being transmitted by line 8 to a monitor 9 which is comprised of a display 10, audible and visual alarms 11 to warn of emergencies if preset values of the parameters are attained, and indicators 12 to diagnose myocardial impairment, dysfunction, and critical illness from the attainment of specific values of cardiac efficiency, myocardial oxygen consumption, and cardiac work.
- Inputs from keyboard 5 may be used to select from among the various diagrams for display by display 10 along with plotted points representing instant conditions of a monitored subject.
- the signal displayed by display 10 and the audio and visual alarms 11 and the signals displayed by indicator 12 are transmitted on line 14 to a printer 13 for producing hard copies and on line 16 to a modem 15 for transmission over telephone lines to central storage.
- a memory 17 in the computer 4 serves as storage of all information and data.
- FIGS. 1 and 2 collectively, data shown in Table 1, as published by J. W. Biondi, et al. in an article entitled The Effect of Incremental Positive End-Expiratory Pressure on Ri ⁇ ht Ventricular He odynamics and Ejection Fraction. Anesthesia
- Analgesia 1988; 67:144-151, on patients with acute respiratory disease are used to demonstrate the utility of efficiency and performance diagrams to diagnose myocardial impairment, dysfunction, and critical illness from right ventricular data.
- PEEP positive end- expiratory pressures
- the computer 4 receives input signals representative of EDVI, ESVI, SBP, EDP, and HR, processes them to determine EF(V), EF(P) , CF, RMV0 2 , and CP. Subsequently, computer 4 generates a performance and an efficiency diagram. According to the teachings of the instant invention, the cardiac monitor of FIG. 3 by displaying a performance diagram of FIG.
- the cardiac monitor reveals a dysfunction (in this case a respiratory disease) as RMV0 2 significantly exceeds the basal RMV0 2 .
- No myocardial impairment is revealed by the cardiac monitor for no PEEP treatment and for PEEP treatments not exceeding 10 cm H 2 0 since cardiac efficiencies for the respective treatments exceed the basal cardiac efficiency below which impairment is indicated.
- the cardiac monitor reveals a PEEP of 5 cm H 2 0 as the most beneficial pressure to elevate cardiac efficiency to its highest levels.
- the cardiac device of FIG. 3 by displaying an efficiency diagram of FIG.
- the cardiac monitor containing a data point representing an instant condition of a monitored subject, reveals depressed volume efficiencies which are compensated by elevated pressure efficiencies to result in an over-all normal cardiac efficiency for no PEEP treatment and PEEP treatments not exceeding 10 cm H 2 0.
- the cardiac monitor also detects a concomitant volume efficiency and pressure efficiency deterioration for PEEP of 20 cm H 2 0 resulting in an abnormally low cardiac efficiency representative of myocardial impairment.
- the cardiac monitor thus, allows the design of specific therapies affecting myocardial impairment through volume efficiency and pressure efficiency, and design of therapies affecting dysfunctions and the monitoring of these therapies.
- FIG. 4 there is plotted pressure efficiency as a representation of cardiac efficiency and SBPI*HR as a representation of MV0 2 for the left heart for two groups of subjects of different ages exercising on a treadmill.
- the symbols denote time on the treadmill as follows v at rest prior to commencement of the treadmill test, ⁇ stage 1, sub-maximal response, D stage 2 sub-maximal response, ⁇ stage 3 sub-maximal response, ⁇ maximal response.
- Subjects of the younger age group utilize a smaller amount of oxygen more efficiently as compared to the subject of older age.
- a threshold efficiency is attained prior to maximal exertion.
- the cardiac monitor of FIG. 3 allows the design of exercise programs, for example, for cardiac rehabilitation and for competitive athletes at the threshold of maximum efficiency to assure safety of cardiac patients and progress in the conditioning program of athletes.
- FIG. 5 there is shown the performance diagram, created by the monitor of FIG. 3 which uses data from Table 3 , of a group of patients in whom anesthesia is administered, where v denotes the state prior to anesthesia and ⁇ the state after anesthesia administration by the drug Propofol- Fentanyl.
- the patient shows a decreased cardiac efficiency representative of myocardial impairment caused by the anesthesia.
- the cardiac monitor has utility to design therapies and monitor efficacy of therapies, drug interventions and the safety of patients.
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Business, Economics & Management (AREA)
- General Business, Economics & Management (AREA)
- Epidemiology (AREA)
- General Health & Medical Sciences (AREA)
- Medical Informatics (AREA)
- Primary Health Care (AREA)
- Public Health (AREA)
- Measuring And Recording Apparatus For Diagnosis (AREA)
Abstract
A diagnostic and monitoring device is used to diagnose myocardial impairment, dysfunctions, and the state of critical illness. The device has utility to design and monitor therapies for differential treatment of myocardial impairment, dysfunctions, rehabilitation, and conditioning exercises. Ventricular size, pressures, and heart rate are measured (2) to determine efficiency components, cardiac work and myocardial oxygen consumption, the data being displayed (10) in efficiency, and performance diagrams to diagnose myocardial impairment from cardiac efficiency data, dysfunctions from myocardial oxygen consumption data, and the state of critical illness from cardiac work data.
Description
METHOD AND APPARATUS FOR MEASURING MYOCARDIAL IMPAIRMENT AND DYSFUNCTIONS FROM EFFICIENCY AND PERFORMANCE DIAGRAMS
BACKGROUND OF THE INVENTION
1. Field of the Invention; The present invention relates to a cardiac monitor and, more specifically, to a method and apparatus for diagnosis of the degree of myocardial impairment, dysfunction, and the state of critical illness of a subject from efficiency and performance diagrams.
2. Description of Prior Art: Present hemodynamic evaluation of a subject includes the measurement of a plurality of parameters such as cardiac pressure, heart rate, cardiac output, and pulmonary and vascular resistance and a determination whether these parameters fall into an empirically established normal range. Each parameter is representative of only a specific aspect of the entire cardiocirculatory system. Therefore, hemodynamic measurements fail to provide an over-all assessment of the system due to the absence of the synergy of the measured data. Ambiguous diagnosis may result from these types of hemodynamic measurements.
Disclosed in U.S. Patent 5,370,122 is a method and an apparatus to establish the synergy of measured parameters in the form of cardiac pressure- size curves. Deviations of instant pressure-size curves from basal pressure-size curves produce changes in the numerical values of cardiac efficiency,
indicative of myocardial impairment, and in the numerical values of cardiac work, indicative of dysfunctions. Not disclosed in the '122 patent, however, is the synergy of cardiac efficiency, myocardial oxygen consumption and cardiac power into a single reference frame allowing for diagnosis of dysfunctions, myocardial impairments and critical illness.
It is an object of the present invention to provide an efficiency diagram for diagnosing myocardial impairment and facilitating the design of therapies affecting myocardial impairment and for monitoring the efficacy of these therapies.
It is another object of the present invention to determine more specifically pressure efficiency and volume efficiency from the efficiency diagram to differentially design and/or monitor the efficacy of therapies affecting pressure efficiency and volume efficiency for improvement of cardiac efficiency. It is still another object of the present invention to provide a performance diagram for diagnosing dysfunctions and critical illness to allow the design of therapies affecting dysfunctions and the critical illness and/or the monitoring of these therapies.
SUMMARY OF THE PRESENT INVENTION According to the present invention there is provided a cardiac diagnostic device for diagnosis of
myocardial impairment, dysfunctions, and critical illness. The device provides means for producing and measuring signals representative of ventricular size, pressures, time intervals of heart beat, and heart rate from a subject, means for processing said signals, means to determine efficiency and performance diagrams from the processed signals, means for determining pressure, volume, and cardiac efficiencies from the efficiency diagram for diagnosing myocardial impairment, means for determining cardiac work, ventricular energy, and myocardial oxygen consumption for diagnosing dysfunctions and critical illness from the performance diagram, means for standardizing ventricular work and ventricular energy and ventricular myocardial oxygen consumption with respect to preselected reference values, and means such as audible or visual signals to alert upon the attainment of specific levels of myocardial impairment and dysfunctions or critical illness. BRIEF DESCRIPTION OF THE DRAWINGS
The present invention will be more fully understood in conjunction with the detailed description of the accompanying drawings in which:
FIG. 1 illustrates an efficiency diagram used to determine cardiac efficiencies and its components volume efficiency and pressure efficiency for diagnosing myocardial impairment;
FIG. 2 illustrates a performance diagram used to determine ventricular energy, its metabolic equivalent of myocardial oxygen consumption, and cardiac work for diagnosing dysfunctions and the state of critical illness;
FIG. 3 shows a block diagram of the apparatus to practice the instant invention;
FIG. 4 illustrates the utility of the present invention to diagnose cardiac efficiency of an exercising subject, to design rehabilitation and exercising programs, and to determine the intensity levels for beneficial exercise; and
FIG. 5 illustrates the utility of the present invention to diagnose myocardial impairment and dysfunction, design and monitoring of therapies, and drug interventions.
DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENT As disclosed in U.S. Patent 5,370,122, cardiac work per one heart beat (W) is given by the equation:
W = (EDVI-ESVI) * (SBP-EDP) (1) where:
EDVI is the end-diastolic volume index, ESVI is the end-systolic volume index, SBP is the systolic blood pressure, and
EDP is the end-diastolic pressure. EDVI and ESVI may be expressed as the ratio of end- diastolic volume, EDV/BSA and end-systolic volume
ESV/BSA where BSA is the body surface area. Cardiac efficiency (CF) is given by the ratio of cardiac work (W) and the ventricular energy available for conversion to work (EDVI*SBP) CF = (EDVI-ESVI./EDVI * (SBP-EDP)/SBP (2) which may be rewritten as
CF = EF(V) * EF(P) (3) where EF(V) = (EDVI-ESVI)/EDVI is the volume efficiency and EF(P) = (SBP-EDP)/SBP is the pressure efficiency. Cardiac work expended during the time of one heart beat is given by the ratio of W and the time required for one beat (RR) . Similarly, cardiac work per minute (CP) is given by the product of W and heart rate (HR) . CP = W*HR (4)
Combining equations (1) , (2) , and (4) yields
CP = CF * EDVI*SBP*HR (5) which indicates that a fraction (CF) of the available ventricular energy per minute, EDVI*SBP*HR, is converted to expend CP. It is noted that 1 liter of oxygen is consumed for the liberation of 4.82 kcal of energy. This relation allows conversion of EDVI*SBP*HR into myocardial oxygen consumption (MV02) and, accordingly, CP = CF * MV02 (6) subject to a conversion factor.
Inserting data published for normals at rest in Ciba-Geigy Scientific Tables, Ciba-Geigy
Corporation, Medical Education Division, West Caldwell, NJ 07006, ISBN 0-914168-54-1, 1990 yields basal values, for example, for the right heart EF(V) = 60%, EE(P) = 50%, CF = 30%, and CP = 0.71*106 erg/m2*sec and for the left heart EF(V) = 63%, EF(P) = 93%, CF = 60% and CP = 6.38*106 erg/m2*sec. These basal CP values are used as standards for right and left ventricle (heart) , respectively, and assigned a unit of 1 CMET/sec. As a corollary, life cannot be sustained if the basal CP is not expended. A patient becomes critically ill if CP < 1 CMET/sec. All present readings for a subject are presented as a multiple of 1 CMET/sec.
Inserting the basal values CF = 30 % and CP = 1 CMET/sec for the right heart into equation 6 yields RMV02 = 3.33 CMET/sec which is the basal myocardial oxygen consumption of the right ventricle. Upon the occurrence of a dysfunction, CP expenditure increases to compensate said dysfunction, which, according to equation (6) , requires MV02 to increase. As a corollary, MV02 greater than the basal value of 3.33 CMET/sec diagnoses a dysfunction.
Referring now to FIG. 1, in an efficiency diagram volume efficiency is plotted versus pressure efficiency. Curves are added to interconnect points in the efficiency diagram having equal values of the product EF(V) and EF(P) or equal values of CF, according to equation (3) . Further, basal values of volume and pressure efficiency are added to the
efficiency diagram as horizontal and vertical lines. The bold CF curve in FIG. 1 indicates basal cardiac efficiency, for example, for the right ventricle, for which CF = 30 %. A myocardial impairment exists if CF does not attain values as indicated by the basal CF curve. As will be apparent to those skilled in the art, the cardiac efficiency diagram for the left heart will have a basal cardiac efficiency, for example, of CF=60% and a plurality of similar curves for the left heart having different values for efficiency and myocardial oxygen consumption may be shown in a similar manner for that displayed in the right heart in FIG. 1. The efficiency diagram curves can be produced either as a function of the computer program or as a transparent overlay on the monitor.
Referring now to FIG. 2, in a performance diagram CF is plotted versus EDVI*SBP*HR or, alternatively, versus MV02. Curves are added to interconnect points in the performance diagram having equal values of CP. Further, basal values for CF and MV02 are added as horizontal and vertical lines. A myocardial impairment exists below the horizontal line, a dysfunction exists to the right of the vertical line, and a patient is critically ill in the zone defined by the CP = 1 CMET/sec curve and the CP = 0.5 CMET/sec curve. The patient is near death when approaching the CP = 0.5 CMET/sec curve. The curves of the performance diagram can be produced either as a function of the
computer program or as a transparent overlay on the monitor.
The embodiment, as shown in FIG. 3 illustrates the teachings of the instant invention. Accordingly, sensors 2 are placed on a subject 1 to detect signals representative of end-diastolic volume, end-systolic volume, systolic blood pressure, end- diastolic blood pressure, time for one heart cycle, and heart rate which are transmitted on multi-line wire 3 to computer 4. Such sensors 2 may include catheters, ultra-sound equipment, and pressure transducers as required for differential assessment of the left or right heart. Additional input representative of patient information including weight, height, body surface area, and preselected basal values is provided from a keyboard 5 to computer 4 on line 6. Computer 4 is programmed to process all incoming signals for determination of volume efficiency, pressure efficiency, cardiac efficiency, cardiac work, ventricular energy, and ventricular myocardial oxygen consumption, said parameters being transmitted by line 8 to a monitor 9 which is comprised of a display 10, audible and visual alarms 11 to warn of emergencies if preset values of the parameters are attained, and indicators 12 to diagnose myocardial impairment, dysfunction, and critical illness from the attainment of specific values of cardiac efficiency, myocardial oxygen consumption, and cardiac work. Inputs from
keyboard 5 may be used to select from among the various diagrams for display by display 10 along with plotted points representing instant conditions of a monitored subject. The signal displayed by display 10 and the audio and visual alarms 11 and the signals displayed by indicator 12 are transmitted on line 14 to a printer 13 for producing hard copies and on line 16 to a modem 15 for transmission over telephone lines to central storage. A memory 17 in the computer 4 serves as storage of all information and data.
Referring now to FIGS. 1 and 2 collectively, data shown in Table 1, as published by J. W. Biondi, et al. in an article entitled The Effect of Incremental Positive End-Expiratory Pressure on Riσht Ventricular He odynamics and Ejection Fraction. Anesthesia
Analgesia 1988; 67:144-151, on patients with acute respiratory disease are used to demonstrate the utility of efficiency and performance diagrams to diagnose myocardial impairment, dysfunction, and critical illness from right ventricular data.
Table 1 PEEP 0 cm H20 5 cm H20 10 cm H20 20 cm H20
V » D ■
SBP mm Hg 39 43 44 48
EDP mm Hg 6 7 6 8
EDVI ml/m2 103 92 95 113
ESVI ml/m2 60 48 55 79
HR 1/min 101 102 103 103
EF(V) % 42 48 42 30
EF(P) % 79 84 77 75
CF % 33 40 32 23
MV02 CMET/sec 12.7 12.6 13.5 17.6
CP CMET/sec 4.2 5.1 4.4 3.9
These patients were treated with positive end- expiratory pressures (PEEP) of varying magnitudes indicated by the symbols v no PEEP, ▼ 5 cm H20 PEEP, D 10 cm H20 PEEP, and ■ 20 cm H20 PEEP. The computer 4 receives input signals representative of EDVI, ESVI, SBP, EDP, and HR, processes them to determine EF(V), EF(P) , CF, RMV02, and CP. Subsequently, computer 4 generates a performance and an efficiency diagram. According to the teachings of the instant invention, the cardiac monitor of FIG. 3 by displaying a performance diagram of FIG. 1 reveals a dysfunction (in this case a respiratory disease) as RMV02 significantly exceeds the basal RMV02. No myocardial impairment is revealed by the cardiac monitor for no PEEP treatment and for PEEP treatments not exceeding 10 cm H20 since cardiac efficiencies for the respective treatments exceed the basal cardiac efficiency below which impairment is indicated. Still further, the cardiac monitor reveals a PEEP of 5 cm H20 as the most beneficial pressure to elevate cardiac efficiency to its highest levels.
In another aspect of the teachings of the present invention the cardiac device of FIG. 3 by displaying an efficiency diagram of FIG. 1, containing a data point representing an instant condition of a monitored subject, reveals depressed volume efficiencies which are compensated by elevated pressure efficiencies to result in an over-all normal cardiac efficiency for no PEEP treatment and PEEP treatments not exceeding 10 cm H20. The cardiac monitor also detects a concomitant volume efficiency and pressure efficiency deterioration for PEEP of 20 cm H20 resulting in an abnormally low cardiac efficiency representative of myocardial impairment. The cardiac monitor, thus, allows the design of specific therapies affecting myocardial impairment through volume efficiency and pressure efficiency, and design of therapies affecting dysfunctions and the monitoring of these therapies.
In still another embodiment of the present invention representations of CF in form of EF(V),
EF(P) , and EF(A) = (EDAI-ESAI)/EDAI and representations of MV02 in form of EDVI*HR, SBPI*HR, where SBPI equals the ratio of pressure to body surface area, EDAI*SBP*HR, where EDAI equals the end-diastolic cross- sectional area referenced to BSA of the ventricle end ESAI = the end-systolic cross-sectional area referenced to BSA may be used, respectively, for the left heart and the right heart, as well as the substitution of
ventricular pressures by arterial pressures, right ventricular pressure by pulmonary artery pressure or central venous pressure, left ventricular systolic pressure by arterial systolic and left ventricular diastolic pressure by wedge pressure or arterial diastolic pressure to determine efficiency and performance diagrams for right and left ventricles.
Referring now to Table 2, there are listed heart rate and blood pressure data as published by R. A. Wolthuis et. al . in an article entitled, The response of healthy men to treadmill exercise,, Circulation 1977;55:153-157, which were used to determine left ventricular myocardial oxygen consumption and pressure efficiency to practice the instant invention to design and monitor rehabilitation and conditioning exercise programs.
Table 2 Age 26 years 47 years
BSA [m2] rest 1.77 2.13
SBP [mm Hg] rest 115 140
SBP(l) [mm Hg] sub-maximal 132 174
SBP(2) [mm Hg] sub-maximal 148 193
SBP (3) [mm Hg] sub-maximal 160 208
SBP [mm Hg] maximal 164 216
EDP [mm Hg] rest 80 90
EDP(l) [mm Hg] sub-maximal 68 90
EDP(2) [mm Hg] sub-maximal 65 90
EDP (3) [mm Hg] sub-maximal 60 90
EDP [mm Hg] maximal 60 96
HR [1/min] rest 60 82
HR(1) [1/min] sub-maximal 102 141 HR(2) [1/min] sub-maximal 130 174
HR(3) [1/min] sub-maximal 158 190
HR [1/min] maximal 200 188
EF(P) [%] rest 30 36 EF(P) (1) [%] sub-maximal 48 48
EF(P) (2) [%] sub-maximal 56 53
EF(P) (3) [%] sub-maximal 63 57
EF(P) [%] maximal 63 56
MV02 [CMET/sec] rest 3.33 4.43 MV02(1) [CMET/sec] sub-maximal 6.25 9.46
MV02(2) [CMET/sec] sub-maximal 8.93 13.0
MV02(3) [CMET/sec] sub-maximal 11.73 15.2
MV02 [CMET/sec] maximal 13.3 15.7
CP [CMET/sec] rest 1.0 1.59 CP [CMET/sec] sub-maximal 3.0 4.54
CP [CMET/sec] sub-maximal 5.0 6.89
CP [CMET/sec] sub-maximal 7.39 8.66
CP [CMET/sec] maximal 8.38 8.79
Referring now to the performance diagram shown in FIG. 4, there is plotted pressure efficiency as a representation of cardiac efficiency and SBPI*HR
as a representation of MV02 for the left heart for two groups of subjects of different ages exercising on a treadmill. The symbols denote time on the treadmill as follows v at rest prior to commencement of the treadmill test, ▼ stage 1, sub-maximal response, D stage 2 sub-maximal response, ■ stage 3 sub-maximal response, Δ maximal response. Subjects of the younger age group utilize a smaller amount of oxygen more efficiently as compared to the subject of older age. A threshold efficiency is attained prior to maximal exertion. Thus, the cardiac monitor of FIG. 3 allows the design of exercise programs, for example, for cardiac rehabilitation and for competitive athletes at the threshold of maximum efficiency to assure safety of cardiac patients and progress in the conditioning program of athletes.
Referring now to Table 3, there are listed heart rate and blood pressure data as published by A. S. Phillips et. al. in an article entitled Propofol- Fentanyl anesthesia: A comparison with Isoflurane-
Fentanγl anesthesia in coronary artery bypass grafting and valve replacement surgery. Journal of Cardiothoracic and Vascular Anesthesia 1994;8:289-296, which were used to determine left ventricular myocardial oxygen consumption and pressure efficiency to practice the instant invention to design and monitor drug therapies such as anesthesia.
Table 3
pre-anesthesia post-anesthesia
BSA [m2] 1 . 91 1 . 91
HR [1/min] 61 65 SBP [mm Hg] 127 105
EDP [mm Hg] 66 60
EF(P) [%] 48 43 MV02 [CMET/sec] 3 . 33 2 . 94 CP [CMET/sec] 1. 6 1 . 26
Referring now to FIG. 5, there is shown the performance diagram, created by the monitor of FIG. 3 which uses data from Table 3 , of a group of patients in whom anesthesia is administered, where v denotes the state prior to anesthesia and ▼ the state after anesthesia administration by the drug Propofol- Fentanyl. The patient shows a decreased cardiac efficiency representative of myocardial impairment caused by the anesthesia. Thus, the cardiac monitor has utility to design therapies and monitor efficacy of therapies, drug interventions and the safety of patients.
In yet another embodiment numerous values for each of CF, MV02, CP and their representations may be collected and displayed in time reference frames including the time derivatives to further monitor progress or regress of myocardial impairments and dysfunctions .
While the present invention has been described in connection with the preferred embodiments of the various figures, it is to be understood that other similar embodiments may be used or modifications and additions may be made to the described embodiment for performing the same function of the present invention without deviating therefrom. Therefore, the present invention should not be limited to any single embodiment, but rather construed in breadth and scope in accordance with the recitation of the appended claims.
Claims
1. A cardiac diagnostic device for monitoring a subject, said device including: means for measuring physiological parameters of such subject; means responsive to measurements of physiological parameters of such subject for deriving values of cardiac efficiency and myocardial oxygen consumption; means for establishing a boundary of physiological criticality in a first reference frame of cardiac efficiency versus myocardial oxygen consumption; and means using said cardiac efficiency and myocardial oxygen consumption of such subject for establishing a subject data point in said first reference frame whereby a comparison is allowed between said subject data point and said boundary of physiological criticality.
2. The cardiac diagnostic device according to claim 1 wherein said boundary of physiological criticality includes at least one curve in said first reference frame, said curve containing at least one reference point representing an absence of dysfunction and myocardial impairment.
3. The cardiac diagnostic device according to claim 2 wherein said means responsive to said measurements further derives cardiac pressure efficiency and cardiac volume efficiency for such subject; and wherein said means for establishing a boundary of physiological criticality further establishes at least one cardiac efficiency curve in a cardiac efficiency reference frame of cardiac volume efficiency versus cardiac pressure efficiency, said cardiac efficiency curve containing a basal reference point representing a basal value for cardiac volume efficiency and a basal value for cardiac pressure efficiency; and wherein said means for establishing a subject data point in said first reference frame further establishes a second subject data point in said cardiac efficiency reference frame using said derived cardiac pressure efficiency and cardiac volume efficiency whereby a comparison is allowed between said second subject data point and said cardiac efficiency curve for the left or right heart.
4. The cardiac diagnostic device according to claim 2 wherein said means for establishing a boundary includes a second curve establishing a zone of physiological criticality with said at least one curve at which death is imminent.
5. The cardiac diagnostic device according to claim 2 wherein said at least one curve further establishes a basal level of cardiac work expended, and wherein said means for establishing further provides a plurality of curves representing elevated levels of cardiac work expended relative to said basal level.
6. The cardiac diagnostic device according to claim 3 wherein said cardiac efficiency curve consists of a plurality of cardiac efficiency curves in said cardiac efficiency reference frame.
7. The cardiac diagnostic device according to claim 3 wherein said cardiac efficiency is defined as the product of cardiac volume efficiency and cardiac pressure efficiency.
8. The cardiac diagnostic device according to claim 3 wherein said cardiac efficiency curve represents a cardiac basal efficiency value for all values of cardiac volume efficiency and cardiac pressure efficiency.
9. The cardiac diagnostic device according to claim 1 wherein said measurements of physiological parameters include signals representative of ventricular size, ventricular blood pressure, time for completion of one cardiac cycle, and heart rate.
10. The cardiac diagnostic device according to claim 1 wherein said means responsive to physiological measurements of physiological parameters further derives volume efficiency, pressure efficiency, cardiac work and available energy for conversion to cardiac work.
11. The cardiac diagnostic device according to claim 3 further including using said subject data point and said curve in said first reference frame and second subject data point and said cardiac efficiency curve in said cardiac efficiency frame to design and monitor therapies for differential treatment of myocardial impairment or dysfunction.
12. The cardiac diagnostic device according to claim 3 further including using said subject data point and said curve in said first reference frame and second subject data point and said cardiac efficiency curve in said cardiac efficiency frame to design and monitor exercise programs for cardiac rehabilitation and conditioning of subjects.
13. A method of diagnosing myocardial impairments, dysfunctions and physiological criticality of a subject, said diagnostic method including the steps of: monitoring such subject to obtain measurements representative of physiological parameters; determining cardiac efficiency and myocardial oxygen consumption for such subject using said representative measurements; establishing a boundary of physiological criticality in a first reference frame of cardiac efficiency versus myocardial oxygen consumption; establishing a subject data point in said first reference frame which represents said determined cardiac efficiency and myocardial oxygen consumption for such subject; and comparing said subject data point with said boundary to indicate physiological criticality.
14. The method according to claim 13 including the further steps of: providing at least one curve in said first reference frame containing at least one reference point which represents an absence of dysfunction and myocardial impairment; and comparing said subject data point to said at least one curve to diagnose myocardial impairments and dysfunctions of the left or right heart of such subject using said reference point of said curve.
15. The method according to claim 14 , wherein said diagnosis of impairment is made by comparing the position of said data point with said reference point with respect to said cardiac efficiency of said first reference frame, and wherein said diagnosis of dysfunction is made by comparing the position of said data point with said reference point with respect to said myocardial oxygen consumption of said first reference frame.
16. The method according to claim 14 , including the further steps of: determining cardiac pressure efficiency and cardiac volume efficiency for such subject using said representative measurements; providing at least one cardiac efficiency curve in a cardiac efficiency reference frame of cardiac volume efficiency versus cardiac pressure efficiency, said cardiac efficiency curve containing an basal reference point representing a basal value for cardiac volume efficiency and a basal value for cardiac pressure efficiency; establishing a second subject data point in said cardiac efficiency reference frame using said determined cardiac pressure efficiency and cardiac volume efficiency; comparing said second subject data point with said cardiac efficiency curve to determine more specifically a cardiac condition and to aid in designing therapies affecting said impairments and dysfunctions.
17. The method according to claim 16 wherein said comparison of said second subject data point with said cardiac efficiency curve involves comparing the volume efficiency of said second subject data point with the basal volume efficiency and comparing the pressure efficiency of said second subject data point with the basal pressure efficiency.
18. The method according to claim 16 further including the step of designing and monitoring therapies, exercise and rehabilitation programs in response to said step of comparing.
19. The cardiac diagnostic device according to claim 10, wherein said means for establishing further provides a plurality of progression curves each in one progress reference frame, each of said progression reference frames having one of said derived values versus time, said progression curves containing points representing instant values of said derived values or their time derivatives for such subject at different times during a therapy treatment or an exercise program.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US1997/015807 WO1999012468A1 (en) | 1997-09-08 | 1997-09-08 | Method and apparatus for measuring myocardial impairment and dysfunctions from efficiency and performance diagrams |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US1997/015807 WO1999012468A1 (en) | 1997-09-08 | 1997-09-08 | Method and apparatus for measuring myocardial impairment and dysfunctions from efficiency and performance diagrams |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO1999012468A1 true WO1999012468A1 (en) | 1999-03-18 |
Family
ID=22261574
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/US1997/015807 WO1999012468A1 (en) | 1997-09-08 | 1997-09-08 | Method and apparatus for measuring myocardial impairment and dysfunctions from efficiency and performance diagrams |
Country Status (1)
| Country | Link |
|---|---|
| WO (1) | WO1999012468A1 (en) |
Cited By (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002049510A1 (en) * | 2000-12-21 | 2002-06-27 | Tonino Bombardini | Method and device for the diagnosis and therapy of chronic heart failure |
| US8561870B2 (en) | 2008-02-13 | 2013-10-22 | Ethicon Endo-Surgery, Inc. | Surgical stapling instrument |
| US11756666B2 (en) | 2019-10-03 | 2023-09-12 | Rom Technologies, Inc. | Systems and methods to enable communication detection between devices and performance of a preventative action |
| US11830601B2 (en) | 2019-10-03 | 2023-11-28 | Rom Technologies, Inc. | System and method for facilitating cardiac rehabilitation among eligible users |
| US11887717B2 (en) | 2019-10-03 | 2024-01-30 | Rom Technologies, Inc. | System and method for using AI, machine learning and telemedicine to perform pulmonary rehabilitation via an electromechanical machine |
| US11915816B2 (en) | 2019-10-03 | 2024-02-27 | Rom Technologies, Inc. | Systems and methods of using artificial intelligence and machine learning in a telemedical environment to predict user disease states |
| US11915815B2 (en) | 2019-10-03 | 2024-02-27 | Rom Technologies, Inc. | System and method for using artificial intelligence and machine learning and generic risk factors to improve cardiovascular health such that the need for additional cardiac interventions is mitigated |
| US11923065B2 (en) | 2019-10-03 | 2024-03-05 | Rom Technologies, Inc. | Systems and methods for using artificial intelligence and machine learning to detect abnormal heart rhythms of a user performing a treatment plan with an electromechanical machine |
| US11955221B2 (en) | 2019-10-03 | 2024-04-09 | Rom Technologies, Inc. | System and method for using AI/ML to generate treatment plans to stimulate preferred angiogenesis |
| US11955220B2 (en) | 2019-10-03 | 2024-04-09 | Rom Technologies, Inc. | System and method for using AI/ML and telemedicine for invasive surgical treatment to determine a cardiac treatment plan that uses an electromechanical machine |
| US11955222B2 (en) | 2019-10-03 | 2024-04-09 | Rom Technologies, Inc. | System and method for determining, based on advanced metrics of actual performance of an electromechanical machine, medical procedure eligibility in order to ascertain survivability rates and measures of quality-of-life criteria |
| US11955223B2 (en) | 2019-10-03 | 2024-04-09 | Rom Technologies, Inc. | System and method for using artificial intelligence and machine learning to provide an enhanced user interface presenting data pertaining to cardiac health, bariatric health, pulmonary health, and/or cardio-oncologic health for the purpose of performing preventative actions |
| US11961603B2 (en) | 2019-10-03 | 2024-04-16 | Rom Technologies, Inc. | System and method for using AI ML and telemedicine to perform bariatric rehabilitation via an electromechanical machine |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5370122A (en) * | 1992-11-18 | 1994-12-06 | Kunig; Horst E. | Method and apparatus for measuring myocardial impairment, dysfunctions, sufficiency, and insufficiency |
| US5584298A (en) * | 1993-10-25 | 1996-12-17 | Kabal; John | Noninvasive hemodynamic analyzer alterable to a continuous invasive hemodynamic monitor |
-
1997
- 1997-09-08 WO PCT/US1997/015807 patent/WO1999012468A1/en active Application Filing
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5370122A (en) * | 1992-11-18 | 1994-12-06 | Kunig; Horst E. | Method and apparatus for measuring myocardial impairment, dysfunctions, sufficiency, and insufficiency |
| US5584298A (en) * | 1993-10-25 | 1996-12-17 | Kabal; John | Noninvasive hemodynamic analyzer alterable to a continuous invasive hemodynamic monitor |
Cited By (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002049510A1 (en) * | 2000-12-21 | 2002-06-27 | Tonino Bombardini | Method and device for the diagnosis and therapy of chronic heart failure |
| US6859662B2 (en) | 2000-12-21 | 2005-02-22 | Tonino Bombardini | Method and device for the diagnosis and therapy of chronic heart failure |
| US8561870B2 (en) | 2008-02-13 | 2013-10-22 | Ethicon Endo-Surgery, Inc. | Surgical stapling instrument |
| US11756666B2 (en) | 2019-10-03 | 2023-09-12 | Rom Technologies, Inc. | Systems and methods to enable communication detection between devices and performance of a preventative action |
| US11830601B2 (en) | 2019-10-03 | 2023-11-28 | Rom Technologies, Inc. | System and method for facilitating cardiac rehabilitation among eligible users |
| US11887717B2 (en) | 2019-10-03 | 2024-01-30 | Rom Technologies, Inc. | System and method for using AI, machine learning and telemedicine to perform pulmonary rehabilitation via an electromechanical machine |
| US11915816B2 (en) | 2019-10-03 | 2024-02-27 | Rom Technologies, Inc. | Systems and methods of using artificial intelligence and machine learning in a telemedical environment to predict user disease states |
| US11915815B2 (en) | 2019-10-03 | 2024-02-27 | Rom Technologies, Inc. | System and method for using artificial intelligence and machine learning and generic risk factors to improve cardiovascular health such that the need for additional cardiac interventions is mitigated |
| US11923065B2 (en) | 2019-10-03 | 2024-03-05 | Rom Technologies, Inc. | Systems and methods for using artificial intelligence and machine learning to detect abnormal heart rhythms of a user performing a treatment plan with an electromechanical machine |
| US11955221B2 (en) | 2019-10-03 | 2024-04-09 | Rom Technologies, Inc. | System and method for using AI/ML to generate treatment plans to stimulate preferred angiogenesis |
| US11955220B2 (en) | 2019-10-03 | 2024-04-09 | Rom Technologies, Inc. | System and method for using AI/ML and telemedicine for invasive surgical treatment to determine a cardiac treatment plan that uses an electromechanical machine |
| US11955222B2 (en) | 2019-10-03 | 2024-04-09 | Rom Technologies, Inc. | System and method for determining, based on advanced metrics of actual performance of an electromechanical machine, medical procedure eligibility in order to ascertain survivability rates and measures of quality-of-life criteria |
| US11955223B2 (en) | 2019-10-03 | 2024-04-09 | Rom Technologies, Inc. | System and method for using artificial intelligence and machine learning to provide an enhanced user interface presenting data pertaining to cardiac health, bariatric health, pulmonary health, and/or cardio-oncologic health for the purpose of performing preventative actions |
| US11961603B2 (en) | 2019-10-03 | 2024-04-16 | Rom Technologies, Inc. | System and method for using AI ML and telemedicine to perform bariatric rehabilitation via an electromechanical machine |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5810011A (en) | Method and apparatus for measuring myocardial impairment and dysfunctions from efficiency and performance diagrams | |
| US5103828A (en) | System for therapeutic management of hemodynamic state of patient | |
| US7272435B2 (en) | System and method for sudden cardiac death prediction | |
| US5370122A (en) | Method and apparatus for measuring myocardial impairment, dysfunctions, sufficiency, and insufficiency | |
| US6519490B1 (en) | Method of and apparatus for detecting arrhythmia and fibrillation | |
| US7338447B2 (en) | Blood flow oxygen measurement system and method | |
| US9706952B2 (en) | System for ventricular arrhythmia detection and characterization | |
| US20100280396A1 (en) | System for Cardiac Pathology Detection and Characterization | |
| US20120016251A1 (en) | System for Respiration Data Processing and Characterization | |
| GB2281780A (en) | Patient alarm detection using trend vector analysis | |
| WO1999012468A1 (en) | Method and apparatus for measuring myocardial impairment and dysfunctions from efficiency and performance diagrams | |
| US20120150003A1 (en) | System Non-invasive Cardiac Output Determination | |
| Tubau et al. | Impaired left ventricular functional reserve in hypertensive patients with left ventricular hypertrophy. | |
| US6520917B1 (en) | Method and apparatus for measuring functionality of a periodically changing system | |
| WO1990003145A1 (en) | Method and apparatus for diagnosing, treating hypertension | |
| Hagberg | Exercise assessment of arthritic and elderly individuals | |
| Mickelson et al. | Left ventricular dimensions and mechanics in distance runners | |
| Rasmussen et al. | Impaired pulmonary and cardiac function after maximal exercise | |
| Marchitto et al. | A pilot study on secondary anemia in" frailty" patients treated with Ferric Sodium EDTA in combination with vitamin C, folic acid, copper gluconate, zinc gluconate and selenomethionine: safety of treatment explored by HRV non-linear analysis as predictive factor of cardiovascular tolerability | |
| OSBORN | Monitoring respiratory function | |
| Hallock | Lactic acid production during rest and after exercise in subjects with various types of heart disease with special reference to congenital heart disease | |
| Kuo et al. | Raising harmonic variation of arterial pulse in dying rats | |
| RYUJIN et al. | Ventricular Arrhythmias in Children: The Validity of Exercise Stress Tests for Their Diagnosis and Management: THE 8TH CONFERENCE ON PRVENTION FOR RHEUMATIC FEVER AND RHEUMATIC HEART DISEASE | |
| EP1135057A1 (en) | Method and apparatus for measuring functionality of a periodically changing system | |
| Thirumurugan et al. | An experimental study to diagnose coronary artery disease using five treadmill scores |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A1 Designated state(s): CA JP |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
| 122 | Ep: pct application non-entry in european phase | ||
| NENP | Non-entry into the national phase |
Ref country code: CA |